About: Danazol

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Danazol Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. [PubChem] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B46F2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B46F3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B46F4-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Dmowski WP: Danazol. A synthetic steroid with diverse biologic effects. J Reprod Med. 1990 Jan;35(1 Suppl):69-74; discussion 74-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2404115 # Donaldson VH: Danazol. Am J Med. 1989 Sep;87(3N):49N-55N. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2486535 # Jenkin G: Review: The mechanism of action of danazol, a novel steroid derivative. Aust N Z J Obstet Gynaecol. 1980 May;20(2):113-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6998453 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Approximately 24 hours. (en)
http://linked.open...ugbank/indication	For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females. (en)
sameAs	Danazol
Title	Danazol (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/chebi/4315 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/chemspider/26436 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/drugbank/DB01406 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/kegg-drug/D00289 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/national-drug-code-directory/0024-0305-60 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/pubchem-compound/28417 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/pubchem-substance/46506475 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/pharmgkb/PA164749056 http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/wikipedia/Danazol
http://linked.open...mechanismOfAction	As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Danazol also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby reducing ovarian estrogen production. Danazol may also directly inhibits ovarian steroidogenesis; bind to androgen, progesterone, and glucocorticoid receptors; bind to sex-hormone-binding globulin and corticosteroid-binding globulin; and increases the metabolic clearance rate of progesterone. Another mechanism of action by which danazol may use to facilitate regression of endometriosis is by decreasing IgG, IgM, and IgA concentrations, as well as phospholipid and IgG isotope autoantibodies. In the treatment of endometriosis, as a consequence of suppression of ovarian function, danazol causes both normal and ectopic endometrial tissues to become inactive and atrophic. This leads to anovulation and associated amenorrhea. In fibrocystic breast disease, the exact mechanism of action of danazol is unknown, but may be related to suppressed estrogenic stimulation as a result of decreased ovarian production of estrogen. A direct effect on steroid receptor sites in breast tissue is also possible. This leads to a disappearance of nodularity, relief of pain and tenderness, and possibly changes in the menstrual pattern. In terms of hereditary angioedema, danazol corrects the underlying biochemical deficiency by increasing serum concentrations of the deficient C1 esterase inhibitor, resulting in increased serum concentrations of the C4 component of the complement system. (Source: PharmGKB) (en)
http://linked.open...drugbank/packager	Amerisource Health Services Corp. Barr Pharmaceuticals App pharmaceuticals llc Graceway Pharmaceuticals Hospira Inc. Merit Pharmaceuticals North America Genescience LLC Sanofi-Aventis Inc.
http://linked.open.../drugbank/synonym	Cyclomen (en) Danocrine (en) Danazolum (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/68-08-00
http://linked.open...k/foodInteraction	Take without regard to meals. (en)
http://linked.open...ynthesisReference	Clinton, R. and Hanson, A.; US. Patent 3,135,743; June 2, 1964; assigned to Sterling Drug. (en)
foaf:page	http://www.drugs.com/cdi/danazol.html http://www.rxlist.com/cgi/generic/danazol.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B46F9-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B46FF-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B46FE-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B46FB-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B46FC-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B46FD-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B46F7-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4710-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B46F5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B46F8-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B46F6-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Danazol
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4705-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4706-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4700-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4701-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4703-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4702-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4704-363D-11E5-9242-09173F13E4C5
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	17230-88-5 (en)
http://linked.open...gbank/containedIn	Danazol 200 mg capsule CVS Pharmacy sam-e 400 mg tablet Cyclomen 50 mg Capsule Cyclomen 100 mg Capsule Danazol 50 mg capsule Cyclomen 200 mg Capsule Danazol 100 mg capsule Danocrine 200 mg capsule
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B470B-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B470D-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B470E-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B470F-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B470A-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4709-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B470C-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B46FA-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B4707-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4708-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software